Fig. 3: HDAC7 upregulates EphA2 by suppressing miR-4465 expression in NPC cells.

a Western blot and qRT-PCR showing the levels of EphA2 protein and mRNA in the shHDAC7 HK1 and 5–8F cells and their control cells. b Western blot showing the levels of EphA2 in the shHDAC7 HK1 and 5–8F cells and control cells treated by 50 μM chloroquine (CQ) and 20 μM MG132, respectively. c QRT-PCR showing the levels of EphA2 hnRNAs in the shHDAC7 HK1 and 5–8F cells and control cells. d Western blot showing the levels of EphA2 in the HK1 and 5–8F cells transfected with 100 nM miR-4465 mimic or mimic control. e QRT-PCR showing the levels of miR-4465 in the shHDAC7 HK1 and 5–8F cells and control cells. f Western blot showing the levels of EphA2 in the shHDAC7 HK1 and 5–8F cells transfected with 200 nM miR-4465 inhibitor or inhibitor control. g 3′UTR dual-luciferase reporter assay. (Top) The predicted miR-4465 binding sites in the 3′UTR of wild-type (WT) EphA2 and mutant EphA2 3′UTR are shown; (bottom) luciferase activity of WT and mutant EphA2 3′UTR dual-luciferase reporter vector in the HEK293 cells transfected with control or miR-4465 mimic. Means, SDs, and statistical significance are denoted; **P < 0.01; ***P < 0.001; ns no significance.